Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference

Avalo Therapeutics (NASDAQ:AVTX) used a presentation at its 46th Annual Healthcare Conference appearance to outline its strategy for AVTX-009, a high-affinity human monoclonal antibody designed to ...
FierceBiotech

Phase 2 data will drive biopharma VC investments next year: PitchBook

Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to prioritize ...
Nasdaq

Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

BERKELEY HEIGHTS, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a ...
Nasdaq

Vigil Neuroscience Advances VG-3927 into Phase 2 Trial as a Promising Once-Daily Oral Therapy for Alzheimer's Disease Following Positive Phase 1 Results

Vigil Neuroscience, Inc. announced positive Phase 1 clinical trial results for VG-3927, a potential once-daily oral therapy for Alzheimer’s disease (AD). The trial demonstrated favorable safety, ...